

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 June 2025 (19.06.2025)



(10) International Publication Number
WO 2025/128722 A2

(51) International Patent Classification:
A61K 48/00 (2006.01) *C12N 9/22* (2006.01)

(21) International Application Number:
PCT/US2024/059602

(22) International Filing Date:
11 December 2024 (11.12.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/608,616 11 December 2023 (11.12.2023) US
63/618,090 05 January 2024 (05.01.2024) US
63/625,640 26 January 2024 (26.01.2024) US
63/626,486 29 January 2024 (29.01.2024) US
63/642,047 03 May 2024 (03.05.2024) US
63/698,812 25 September 2024 (25.09.2024) US
63/705,442 09 October 2024 (09.10.2024) US

(71) Applicant: **MYELOID THERAPEUTICS, INC.**
[US/US]: 300 Technology Square, Suite 203, Cambridge,
Massachusetts 02139 (US).

(72) Inventors: **GETTS, Daniel**; c/o Myeloid Therapeutics,
Inc., 300 Technology Square, Suite 203, Cambridge, Mass-
achusetts 02139 (US). **WANG, Yuxiao**; c/o Myeloid Ther-
apeutics, Inc., 300 Technology Square, Suite 203, Cam-
bridge, Massachusetts 02139 (US). **LIN, Ruci-Zeng**; c/o
Myeloid Therapeutics, Inc., 300 Technology Square, Suite
203, Cambridge, Massachusetts 02139 (US).

(74) Agent: **TORRANCE, Blake Lamar** et al.; Wilson Sonsi-
ni Goodrich & Rosati, 650 Page Mill Road, Palo Alto, Cal-
ifornia 94304 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,

(54) Title: METHODS AND COMPOSITIONS FOR GENOMIC INTEGRATION




FIG. 16C

(57) Abstract: Methods and compositions for modulating a target genome and stable integration of a transgene of interest into the genome of a cell are disclosed. Specifically, provided herein comprises compositions comprising an RNA molecule comprising a reverse complement sequence comprising an exogenous sequence and homology arms, an RNA molecule comprising an endonuclease, and one or more guide RNAs for specific genomic integration of the exogenous sequence.

[Continued on next page]

MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*